COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25/03/2024
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) AXS-12 [...]
Nkarta Announces Pricing of $240 Million Underwritten Offering
25/03/2024
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an [...]
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
25/03/2024
Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis Presented late-breaking [...]
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
25/03/2024
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in January of 2024 as [...]
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
25/03/2024
VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform SOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) -- [...]
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
25/03/2024
Bagsværd, Denmark, and Han n over, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront [...]
Novo Nordisk A/S - Articles of Association 2024
25/03/2024
Novo Nordisk's Articles of Association 2024 Attachment Articles of Association 21 Mar 2024
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation
25/03/2024
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation First medical device company to become a corporate champion at the [...]
Nyxoah Fait Progresser sa Stratégie d'Accès aux Patients en Annonçant un Partenariat Stratégique avec l'American Association of Otolaryngology – Head & Neck Surgery Foundation
25/03/2024
Nyxoah Fait Progresser sa Stratégie d'Accès aux Patients en Annonçant un Partenariat Stratégique avec l'American Association of Otolaryngology – Head & Neck Surgery Foundation Première société de dispositifs [...]
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
25/03/2024
MOJAVE – US Phase 1/2a study of DSR 2.0 for treatment of heart failure Previously reported strong data maintained after three-months follow-up: Diuretic response remained nearly normalized, with a mean increase of 326% [...]
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
25/03/2024
Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) [...]
Valneva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son rapport annuel américain « Form 20-F »
25/03/2024
Saint-Herblain (France), 25 mars 2024 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui le dépôt, le 22 mars 2024, de son Document d’enregistrement universel [...]
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
25/03/2024
Oslo, March 25, 2024, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") at 14:00 CET on April 18, 2024. The General Meeting will be held electronically. For [...]
Congress Passes Bills Making Major Investments in Alzheimer’s
23/03/2024
Bill Increases Funding for Alzheimer’s Research and Prevention Efforts WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22/03/2024
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22/03/2024
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and [...]
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
22/03/2024
Leading Contract Research Organization to carry out pharmacological studies, part of planned FDA Investigational New Drug (IND) application TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic [...]
Vistin Pharma ASA: Mandatory notification of trade
22/03/2024
Pactum Vekst AS has on March 22, 2024 sold 527 960 shares in Vistin Pharma ASA at a price of NOK 22,10 per share. Espen W. Marcussen, Chair of the board in Pactum Vekst AS, is a primary insider and board member of [...]
Nutra Pharma Corp. Reaches Settlement with SEC
22/03/2024
Nutra Pharma Corp. has reached a bifurcated settlement with the SEC along with its CEO and a Consultant to the company CORAL SPRINGS, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC: NPHC), (“ [...]

Pages